Navigation Links
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
Date:10/3/2008

Companies to Study B-Raf Kinase Inhibitors for Cancer Treatments

INDIANAPOLIS, Ind. and LAWRENCE, Kan., Oct. 3 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and privately-held Deciphera Pharmaceuticals, LLC today announced that the two companies have entered into a collaboration and worldwide licensing agreement related to Deciphera's preclinical B-Raf kinase inhibitor program for the study of potential oncology therapeutics.

The collaboration will apply Deciphera's phylomechanics discovery platform, a unique, proprietary approach to kinase inhibitor design, together with Lilly's expertise in discovery, development and commercialization to pursue first-in-class and best-in-class drug candidates for a variety of cancers.

Under the terms of the agreement, Lilly and Deciphera will collaborate in four different project areas involving selective or multi-kinase targeted B-Raf inhibitors. Lilly will obtain exclusive worldwide rights to any products developed as part of this collaboration. In return, Deciphera will receive an upfront payment and research funding over the next two years from Lilly, and may also receive up to $130 million in potential development, regulatory and sales milestones for each of the four project areas. If a product is successfully commercialized from this collaboration, Deciphera will be entitled to royalties on sales.

"This collaboration is further evidence of Lilly's ongoing commitment to oncology research," said Dr. William W. Chin, M.D., vice president of discovery research and clinical investigation for Lilly. "We look forward to working with Deciphera to leverage their B-Raf kinase inhibitor program, with the ultimate goal of developing promising drug candidates for canc
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Lilly and TransPharma Medical Announce Licensing and Development Agreement
6. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
8. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
9. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
10. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
11. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  ResMed (NYSE: RMD ) ... agreement to acquire Curative Medical, a privately-held ... breathing medical devices and accessories. ... leadership in sleep and respiratory medicine, will ... suffering from sleep-disordered breathing and ...
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 /PRNewswire/ ... Novartis /Alcon executives have recently contacted the Company ... will begin as early as Monday, August 3, ... been quoted as saying that the coming electronic ... billions of dollars over the next several years.  ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... 2011 BD (Becton, Dickinson and Company) ... technology company, announced today that it is donating $325,000 ... earthquake and tsunami in Japan. BD will distribute these ... AmeriCares, American Red Cross, Direct Relief International, Heart to ...
... March 15, 2011 New Image Global, Inc., ... recently joined forces with the disability advocacy group, ... donated artificial limbs to candidates disabled by amputation ... manufacturing facility in Santiago, Dominican Republic.) Under the ...
Cached Medicine Technology:BD Donates $325,000 for Japan Earthquake and Tsunami Relief Efforts 2
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic ... across Georgia through the Girl Scout "Be a Friend First" program. Representatives from Peach ... 30. , “Peach State Health Plan and our parent company, Centene Corporation, are ...
(Date:7/31/2015)... ... , ... Like nearly every other form of surgery, it shouldn't come as ... and less intrusive and painful. Leading these advances in the United States has ... stands as the only doctor in the United States who is qualified to practice, ...
(Date:7/31/2015)... ... 31, 2015 , ... Florida Hospital Tampa has started treating ... for targeted delivery of fluids to selected sites in the peripheral vascular system. ... with the device that provides direct, local delivery of chemotherapy to the pancreas. ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to WFLA on July ... heroin use and eventual overdoses. Thricefold deaths have held steady over the last “couple ... the Sarasota heroin epidemic, which was spurred by the crackdown of prescription painkillers. Many ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... and other chemicals boost their odds of respiratory ... News) -- Frequent exposure to hospital cleaning products ... according to a U.S. study that included 3,650 ... The researchers found that nurses regularly exposed to ...
... 20 MPR ( Monthly Prescribing Reference ) is pleased to ... For over 25 years, physicians and other healthcare professionals ... our drug database for up-to-date, concise drug information at the point-of-care.The ... will also offer a number of added features and functionality: , ...
... Jan. 20 Northern Trust announced today,that it ... North Shore-LIJ Health,System, the nation,s third largest not-for-profit ... custodian, benefit payment, plan accounting,and investment risk and ... invested funds. , "North ...
... IT pioneer doubles annual revenues, brings on hundreds of ... today announced 200 percent revenue growth in 2008. ... system, integrated delivery network (IDN) and health information exchange ... bookings and the addition of some 200 hospitals to ...
... to target only the tumor, researchers explain , , ... therapy that uses beads soaked with anti-cancer agents has ... studies. , Transarterial chemoembolization (TACE) attacks liver ... cancer-killing chemotherapeutic agents are delivered to the blood vessel ...
... /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) (,Renhuang, ... People,s Republic of China (,PRC,),today announced that it ... new,independent auditor, effective January 9, 2009. Moore ... was dismissed on the same,day. , ...
Cached Medicine News:Health News:Cleaning Products Up Nurses' Asthma Risk 2Health News:MPR Re-Launches its Up-to-Date Drug Reference Website 2Health News:Northern Trust Named Global Custodian to North Shore-LIJ Health System in New York 2Health News:Carefx Reports 200% Year-Over-Year Revenue Growth in 2008 as Demand Grows for Solutions Focused on Clinical Decision Making 2Health News:Carefx Reports 200% Year-Over-Year Revenue Growth in 2008 as Demand Grows for Solutions Focused on Clinical Decision Making 3Health News:Tiny Chemo Beads Boost Liver Cancer Outcomes 2Health News:Tiny Chemo Beads Boost Liver Cancer Outcomes 3Health News:Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor 2
... VH series, it is a ... independent C-arms and image intensifiers, ... for Cardiovascular and Angiography. There ... the examinations for cerebral, cardiac, ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Rubidium Rb 82 Generator. ,The only generator-based Positron Emission Tomography agent reimbursed for the evaluation of coronary artery disease....
Kit for the Preparation of Technetium Tc 99m Teboroxime...
Medicine Products: